Join Growin Stock Community!

Neogenomics, inc.NEO.US Overview

US StockHealthcare
(No presentation for NEO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NEO AI Insights

NEO Overall Performance

NEO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NEO Recent Performance

-3.97%

Neogenomics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

NEO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NEO Key Information

NEO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NEO Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Price of NEO

NEO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NEO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.16
PE Ratio (TTM)
-
Forward PE
26.76
PS Ratio (TTM)
1.75
PB Ratio
1.58
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
43.21%
Net Margin
-14.85%
Revenue Growth (YoY)
10.11%
Profit Growth (YoY)
8.34%
3-Year Revenue Growth
11.09%
3-Year Profit Growth
13.62%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.16
PE Ratio (TTM)
-
Forward PE
26.76
PS Ratio (TTM)
1.75
PB Ratio
1.58
Price-to-FCF
-
Gross Margin
43.21%
Net Margin
-14.85%
Revenue Growth (YoY)
10.11%
Profit Growth (YoY)
8.34%
3-Year Revenue Growth
11.09%
3-Year Profit Growth
13.62%

  • When is NEO's latest earnings report released?

    The most recent financial report for Neogenomics, inc. (NEO) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NEO's short-term business performance and financial health. For the latest updates on NEO's earnings releases, visit this page regularly.

  • What is the operating profit of NEO?

    According to the latest financial report, Neogenomics, inc. (NEO) reported an Operating Profit of -13.41M with an Operating Margin of -7.05% this period, representing a growth of 27.1% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is NEO's revenue growth?

    In the latest financial report, Neogenomics, inc. (NEO) announced revenue of 190.17M, with a Year-Over-Year growth rate of 10.56%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does NEO have?

    As of the end of the reporting period, Neogenomics, inc. (NEO) had total debt of 409.46M, with a debt ratio of 0.3. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does NEO have?

    At the end of the period, Neogenomics, inc. (NEO) held Total Cash and Cash Equivalents of 159.62M, accounting for 0.12 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does NEO go with three margins increasing?

    In the latest report, Neogenomics, inc. (NEO) did not achieve the “three margins increasing” benchmark, with a gross margin of 43.8%%, operating margin of -7.05%%, and net margin of -5.2%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess NEO's profit trajectory and future growth potential.

  • Is NEO's EPS continuing to grow?

    According to the past four quarterly reports, Neogenomics, inc. (NEO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NEO?

    Neogenomics, inc. (NEO)'s Free Cash Flow (FCF) for the period is -6.53M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 262.87% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.